Skip to main content

Innovative wound care for better healing and quality of life

About Flen Health

Flen Health is a family-owned biopharmaceutical company, based in Belgium, which has been dedicated to advancing skin and wound-healing solutions for about 25 years. With a strong market presence in Europe and Asia, Flen Health has become a leader in both the UK and Belgium and operates in about 50 countries globally. Our focus on developing cutting-edge wound care solutions has positioned us as a trusted name in chronic wound and skin care.

Our expertise lies in creating advanced treatments based on recombinant enzyme technology, specifically designed to address the challenges of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and severe burns. This proprietary technology works by modulating inflammation and eliminating micro-organisms, an essential advancement for effective chronic wound care.

Our history

Our mission and vision

We are shaping a world where wounds and skin disorders no longer prevent patients from living the lives they love. Through our advanced solutions, we empower both patients and healthcare professionals, enhancing the healing process and elevating quality of life for all those affected.

With about 25 years of expertise, we design reliable, efficient, and easy-to-use wound care products trusted by patients and healthcare professionals worldwide.

Commitment to innovation

At Flen Health, we stand out through our commitment to science, innovation, and personalized care, leveraging advanced technologies to create breakthrough solutions for chronic wounds and skin diseases. 

By investing in rigorous R&D, conducting comprehensive studies, and upholding the highest standards, we address the diverse challenges faced by patients, earning global recognition and prestigious industry awards.

More abour our R&D innovative centre

Patient-centric approach

Our mission is to empower patients and healthcare professionals with safe, effective wound and skin care solutions, supported by thorough training to maximize product effectiveness and outcomes.

Engaging with patients and clinicians provides essential insights, enabling us to refine our products to meet real-world needs and deliver lasting value and meaningful improvements in patient care.

Global expansion and strategic growth

At Flen Health, our vision goes beyond product development; we are committed to expanding our global footprint through targeted initiatives:

  • Establishing affiliates in key markets, with 7 affiliates and 1 joint venture

  • Growing our global presence, reaching 44 distribution countries

  • Achieving a CAGR on net revenues of 10% over the period 2020 – 2023

  • Publishing over 150 case studies and 50+ scientific publications

  • Investing in innovation and diversifying our product portfolio

  • Transitioning into biopharmaceutical to enter the U.S. market

Through these strategies, we ensure our products reach more patients worldwide, enhancing health outcomes on a global scale.

Our biopharmaceutical journey to the US market  

Advancing U.S. Registration of VES Gel

We are progressing toward U.S. registration of VES gel, a biopharmaceutical specifically designed to accelerate healing in chronic diabetic foot ulcers. This advanced treatment combines a patented recombinant enzyme complex in an alginate ointment to modulate inflammation. Additionally, it eliminates bacteria and yeast without development of resistance.

Expanding into the U.S. Market: Leveraging our European experience

With over 25 years of expertise in providing trusted wound care solutions across Europe and around the world, we aim to bring our innovative products to the U.S. market. Our latest development, VES, is currently in the process of meeting FDA standards as a combination product, integrating both medical device and biologic classifications. 

To provide the best possible care for our patients in the U.S., we are developing recombinant enzymes designed to modulate inflammation and accelerate the wound healing process.

Beginning in 2026, we are set to launch clinical trials to support our U.S. launch timeline.

As we enter this market, we seek a strategic partner to support us in the clinical development of this transformative biologic.

Are you driven by offering the best to patients in need? Partner with us! 

Contact us for more information

People who champion our mission and vision

Board of Directors

Claus Zieler
President of the BoD

Philippe Sollie
Vice President of the BoD, CEO, founder at Flen Health

Jacob Agris
Voting member

Jesper Hoiland
Voting member

Benjamin Sollie
Voting member

Philippe Estas
Observer

Robrecht Sollie
Observer

Executive Leadership Team

Robin Nicholson
Head of Commercial Operations

Julie Kerckhof
US Business Strategy Director

Nicolas Deleye
Director International Business Development

Kim Vander Haegen
Finance, Supply Chain, Data Management & IT Director

Contact us for more information

If you're seeking more information about our company, upcoming opportunities, or financial insights, please complete the contact form below. Our team will be in touch with you shortly to address your inquiries and provide the information you need. We look forward to the opportunity to engage with you.

Connect with us

More about Flen Health

Consult our product portfolio

Discover our solutions designed to promote faster healing and improve patient care across a range of skin and wound conditions.

Discover more

Events and conferences

Join us at events we organise and conferences we participate in to connect, collaborate, and stay ahead in the industry!

Meet with us

Flen Health news

Stay updated with the latest developments and insights from Flen Health in our news section.

Discover more